Hematologic Oncology Articles

Ruxolitinib Reaches 55% Response Rate in Pivotal GVHD Trial
Ruxolitinib combined with corticosteroids induced an overall response rate of 55% at day 28 in patients with steroid-refractory acute graft-versus-host disease, meeting the primary endpoint of the phase II REACH1 trial.
Expert Discusses Venetoclax Potential in MCL
Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.
Blinatumomab Granted Full EU Approval for B-cell Precursor ALL
The European Commission has granted blinatumomab full marketing authorization for the treatment of adult patients with Philadelphia chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia, according to Amgen, the developer of the anti-CD19 immunotherapy.
 
Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma
Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.
The addition of elotuzumab to pomalidomide and dexamethasone cut the risk of disease progression or death by 46% compared with pomalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.
Upfront Duvelisib Plus FCR Shows Promise in Younger Patients With CLL
The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.
Quizartinib Extends Survival in FLT3-ITD+ Relapsed/Refractory AML
Quizartinib reduced the risk of disease progression or death by 24% compared with salvage chemotherapy in patients with FLT3-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation.
CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL
A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.
Compound CAR T-Cell Therapy Shows Promise for AML
A compound CLL1/CD33-targeted CAR T-cell therapy showed a complete remission with minimal residual disease (MRD) negativity in a single-patient case study from an ongoing phase I study for relapsed/refractory acute myeloid leukemia.
PET-Guided De-escalation Effective in Advanced Hodgkin Lymphoma
PET can be safely used to guide treatment in patients with untreated advanced-stage classical Hodgkin lymphoma after 2 cycles of upfront de-escalated BEACOPP.
Publication Bottom Border
Border Publication
x